Efficiency of Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration

Efficiency of Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration

Purpose: To evaluate the efficiency of the treatment of intravitreal ranibizumabin on the functions of lesion size and visual outcome in neovascular age-related macular degeneration cases. Material and Methods: Age-related macular degeneration diagnosis of 71eyes of 59 patients were analyzed retrosp...

Full description

Bibliographic Details
Main Authors:	Didem sahin, Ahmet sahin, Adnan Aksoy, Lokman Aslan, Ali simsek
Format:	Article
Language:	English
Published:	Cukurova University 2015-12-01
Series:	Çukurova Üniversitesi Tıp Fakültesi Dergisi
Subjects:	Age-related macular degeneration ranibizumab visual acuity choroidal neovascularization widest lesion diameter
Online Access:	http://www.scopemed.org/fulltextpdf.php?mno=180917

Similar Items

Yaş Tip Yaşa Bağlı Makula Dejenerasyonunda İntravitreal Ranibizumab Enjeksiyonunun Etkinliği
by: Didem ŞAHİN, et al.
Published: (2015-10-01)

Results of Intravitreal Ranibizumab Treatment for Exudative Age-Related Macular Degeneration
by: Umut Karaca, et al.
Published: (2012-01-01)

Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization
by: Sun T, et al.
Published: (2021-06-01)

THE MACULAR HOLE AFTER INTRAVITREAL INJECTIONS OF RANIBIZUMAB IN A PATIENT WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION – A CASE STUDY
by: Magdalena Kal, et al.
Published: (2013-11-01)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01)

Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration
by: Huseyin Serdarogullari, et al.
Published: (2014-05-01)

Comparison of the outcome of limited protocol Ranibizumab injection in naïve choroidal neovascular membranes secondary to pathological myopia versus age-related macular degeneration
by: Samah M Fawzy, et al.
Published: (2023-01-01)

First-Year Outcomes of Cataract Surgery Combined with Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
by: Sabahattin Sül, et al.
Published: (2019-02-01)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
by: Daniel Sanju Narayan, et al.
Published: (2015-01-01)

Long-term outcomes of Ranibizumab treatment in neovascular age-related macular degeneration
by: Burak Simsek, et al.
Published: (2018-02-01)

Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
by: Zhe-Li Liu, et al.
Published: (2013-04-01)

Comparison of efficacy between Ranibizumab and Conbercept for wet age-related macular degeneration
by: Qiang Fan, et al.
Published: (2018-08-01)

Early changes in macular optical coherence tomography parameters after Ranibizumab intravitreal injection in patients with exsudative age-related macular degeneration
by: Nicole Antunes de Almeida, et al.
Published: (2018-02-01)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
by: Hirakata T, et al.
Published: (2016-05-01)

Intravitreal Ranibizumab Therapy in Wet Type Macular Degeneration
by: Hüseyin Dündar, et al.
Published: (2014-10-01)

A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal
by: Rufino Silva, et al.
Published: (2017-06-01)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
by: Dorota Luksa, et al.
Published: (2021-11-01)

Intravitreal Ranibizumab for Subfoveal Choroidal Neovascularization from Age-Related Macular Degeneration with Combined Severe Diabetic Retinopathy
by: So Young Han, et al.
Published: (2015-02-01)

Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration
by: Ying Qin, et al.
Published: (2017-08-01)

Effect of conbercept or ranibizumab in the treatment of wet age-related macular degeneration
by: Dawei Zhang, et al.
Published: (2019-01-01)

Assessment of effect of intravitreal ranibizumab injection on the ocular blood flow in patients with neovascular age-related macular degeneration
by: V. V. Neroev, et al.
Published: (2014-07-01)

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization Secondary to Endogenous Endophthalmitis
by: Shwu-Jiuan Sheu
Published: (2009-11-01)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
by: Christof Haensli, et al.
Published: (2021-06-01)

Role of ranibizumab in management of macular degeneration
by: Singh Rishi, et al.
Published: (2007-01-01)

Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study
by: Sagong M, et al.
Published: (2021-05-01)

Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
by: Jose Navarro-Partida, et al.
Published: (2021-09-01)

Ranibizumab reimbursement and treatment patterns for neovascular age-related macular degeneration in Taiwan – Results from the 12-month, observational RENOWNED study
by: San-Ni Chen, et al.
Published: (2022-10-01)

Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma
by: Zenith H.Y. Wu, et al.
Published: (2012-06-01)

Intravitreal Ranibizumab Therapy for Choroidal Neovascularization Secondary to Pathological Myopia: 3 Year Outcome
by: İrfan Perente, et al.
Published: (2018-04-01)

Clinical efficacy of intravitreal Ranibizumab in idiopathic choroid neovascularization type Ⅰand type Ⅱ
by: Yue-Ming Sun, et al.
Published: (2015-07-01)

Optical coherence tomography findings in macular hole complicating exudative age-related macular degeneration treated with ranibizumab
by: Rosa Dolz-Marco
Published: (2013-08-01)

Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01)

Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence
by: Chakraborty D, et al.
Published: (2023-04-01)

Intravitreal Avastin for managing CNV due to age-related macular degeneration
by: Quan - Liang Zhao, et al.
Published: (2013-05-01)

Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up
by: Yan Lu, et al.
Published: (2021-11-01)

Intravitreal Conbercept or Ranibizumab for myopic choroidal neovascularization
by: Cai-Yun Zhang, et al.
Published: (2022-06-01)

Pachychoroid neovasculopathy can mimic wet type age-related macular degeneration
by: Mohsen Farvardin, et al.
Published: (2022-10-01)

Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration
by: Bekir Küçük, et al.
Published: (2018-04-01)

Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration
by: Simon D Archambault, et al.
Published: (2024-01-01)

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration
by: Partha Biswas, et al.
Published: (2011-01-01)